Abstract
Morbidity and mortality associated with tobacco use re-main a major public health problem. Unfortunately, mo-dern pharmacotherapy for smoking cessation have limited effectiveness, and most smokers repeatedly stop smoking. The better understanding of the neurobiological and neu-rophysiological mechanisms that contribute to the relapse of smoking is necessary for new drugs for the nicotine ad-diction treatment. The review examined preclinical studies aimed at identifying neurotransmitter and neuromodula-tory systems that provide a relapse of nicotine consump-tion. In preclinical studies, the efficacy of regulating extra-cellular neurotransmitters or neurotransmitter receptor activity using antagonists or receptor agonists (both full and partial) has been demonstrated. In particular, it was shown that a drug that selectively binds to acetylcholine receptors containing three α4- and two β2-subunits reduc-es the search for nicotine in rats. It was shown that new pharmacological approaches to reduce the craving for ni-cotine in animal models can be used in the future to re-duce the risks of relapse of nicotine addiction in smokers.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
